Hematology

News

MORE >>>

ELOQUENT-3: Adding Elotuzumab to Pomalidomide, Dexamethasone Improves PFS in R/R Multiple Myeloma

December 08, 2018

Ruxolitinib Results in Better Treatment Response, Less Toxicity in Early Primary Myelofibrosis

December 07, 2018 – Jaime Rosenberg

FDA Approves Targeted Drug to Treat Relapsed or Refractory AML With FLT3 Mutation

December 03, 2018 – Laura Joszt

Epigenetic Changes Are the Main Contributor to Immune Escape in Posttransplantation AML Relapse

November 30, 2018 – David Bai, PharmD

Journals

MORE >>>

Cost Per Response Analysis of Strategies for Chronic Immune Thrombocytopenia

July 11, 2018 – Kelly Fust, MS; Anju Parthan, PhD; Xiaoyan Li, PhD; Anjali Sharma, MD; Xinke Zhang, MS; Marco Campioni, PhD; Junji Lin, PhD, MS; Xuena Wang, PhD; Richard Zur, PhD; Karynsa Cetin, MPH; Melissa Eisen, MD; and David Chandler, PhD

The Importance of Teamwork in Oncology Care Transitions

February 28, 2018 – Surabhi Dangi-Garimella, PhD

Pricing of Monoclonal Antibody Therapies: Higher If Used for Cancer?

February 14, 2018 – Inmaculada Hernandez, PharmD, PhD; Samuel W. Bott, BS; Anish S. Patel, BS; Collin G. Wolf, BS; Alexa R. Hospodar, BS; Shivani Sampathkumar, BS; and William H. Shrank, MD, MSHS